

***Updated:* Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing**

Effective October 17th, 2022

Certain eligible pharmacies can administer publicly funded injectable COVID-19 vaccines to eligible individuals (see Pharmacy Eligibility below).

The purpose of this Executive Officer (EO) Notice (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Billing**), the EO Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**, and the accompanying Questions and Answers (Qs & As) documents, are to set out the terms and conditions for a participating pharmacy's submission of claims for payment (claims) for administering injectable COVID-19 vaccines to eligible individuals. Each document is a ministry policy that pharmacy operators must comply with under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators.

Participating pharmacies must comply with all of the terms and conditions set out in the EO Notices and Qs & As. It is a condition of participating that participating pharmacies offer first, second and third or booster doses to all eligible groups, provided that there is sufficient supply of the vaccines.

The two (2) EO Notices and the accompanying Qs & As documents are **not** intended to describe a pharmacy operator's obligations in respect of administering injectable COVID-19 vaccines under applicable legislation, other agreements with the Province of Ontario, or policies of the OCP. Pharmacy operators with questions about their legal obligations outside of the HNS Subscription Agreement should refer to the applicable legislation, other agreement, or OCP policy as appropriate.

This EO Notice (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Billing**) replaces the previous EO notice on the same topic respecting the administration of publicly funded COVID-19 vaccines in Ontario pharmacies that was effective, September 26th, 2022.

Pharmacy and Patient Eligibility

- Please refer to the [ministry website](#) for the most recent EO Notice entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**”.

General Description

- There is no cost to eligible patients who receive the COVID-19 vaccine when administered at a pharmacy.
- For each valid claim submitted, a pharmacy will receive \$13.00 as payment for providing the following services:
 - Providing the patient with details of the process and answering any questions related to the vaccination.
 - Obtaining the consent of the patient or their substitute decision-maker prior to vaccine administration
 - Administering the COVID-19 vaccine.
 - Providing the patient with proper monitoring and written vaccine information as well as after-care instructions following vaccine administration.
 - Providing the patient with a written receipt of the vaccination with the pharmacy contact information (see below for more details); a pharmacy may wish to issue an electronic receipt as well. (Note: a written receipt can be printed from COVAX_{ON}).
 - Mandatory scheduling of the second dose (where applicable)
 - Complying with any requirements to access and use the Provincial COVID-19 Vaccine Solution-COVAX_{ON} under the COVID-19 Vaccine Agreement.
- Pharmacies may access personal protective equipment (PPE) from the ministry’s dedicated supply, if needed, to administer the COVID-19 vaccine. The ministry’s supply of PPE must ONLY be used to support the activity of pharmacies administering the publicly funded COVID-19 vaccine.
- Table 1 lists the publicly funded COVID-19 vaccines that are available to pharmacies, including any restrictions on administering the vaccine (e.g., age groups)¹.
- For clarity, where a patient meets the eligibility criteria for the vaccine² but is excluded by the restrictions for the vaccine product (see Table 1 below), the vaccine

¹ Inclusion of a product in the list of publicly funded vaccines available for pharmacies does not guarantee supply of the product through the participating pharmaceutical distributors.

² Please refer to the [ministry website](#) for the most recent EO Notice entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**”.

cannot be administered to the patient. If a patient does not meet the eligibility criteria for the vaccine,³ the vaccine cannot be administered to the patient even if they are not excluded by the restrictions. Note that certain eligibility criteria may be specific to a particular vaccine/DIN/PIN.

Table 1: Publicly Funded COVID-19 Vaccine

DIN or PIN	COVID-19 Vaccine Product	Dosage format	Recommended Dosing regimen**	Restrictions**
02512947	COVISHIELD COVID-19 VACCINE Verity Pharmaceuticals Inc.	As per the October 17 th , 2022 update, the DIN 02512947 for COVISHIELD COVID-19 VACCINE is no longer billable.		
09857655	COVID-19 VACCINE AstraZeneca	As per the October 17 th , 2022 update, the PIN 09857655 for COVID-19 VACCINE AstraZeneca is no longer billable.		
02510014	COVID-19 VACCINE MODERNA 0.20mg/mL Moderna Therapeutics Inc. (also known as SPIKEVAX™)	Intramuscular injection solution. Multi-dose vial Dose: 100 MCG / 0.5 mL ⁴ (12 years and older) Dose : 50 MCG / 0.25 mL (6 to 11 years)	2 doses (8 weeks apart)* or 3+ doses (interval varies)*****	6 years of age & older as per product monograph *****
02527685	COVID-19 VACCINE MODERNA 0.10mg/mL	Intramuscular injection solution. Multi-dose vial	2 doses (8 weeks apart)* or	6 months of age & older as per product monograph *****

³ Please refer to the [ministry website](#) for the most recent EO Notice entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**”.

⁴ As per the Notice on the Ministry’s [website](#) entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**”, it is recommended that some individuals receive a half dose (50mcg) for a booster dose. Please refer to that Notice for more information.

DIN or PIN	COVID-19 Vaccine Product	Dosage format	Recommended Dosing regimen**	Restrictions**
	Moderna Therapeutics Inc. (also known as SPIKEVAX™)	Dose: 25 MCG / 0.25 mL (6 months to 5 years) Dose : 50 MCG / 0.5 mL (6 to 11 years)	3+ doses (interval varies)*****	
02530252	COVID-19 BIVALENT VACCINE MODERNA 0.10mg/mL Moderna Therapeutics Inc. (also known as SPIKEVAX BIVALENT™)	Intramuscular injection solution. Multi-dose vial Dose: 50 MCG / 0.5 mL	1 dose at least 6 months after a primary series (i.e., 2-3 doses) or after a previous booster dose *****	18 years of age & older as per product monograph (Note: may also be used off-label for immunocompromised individuals 12-17 years of age)
02509210	PFIZER-BIONTECH COVID-19 VACCINE (12+ formulation) Pfizer Canada ULC (purple cap) (also known as COMIRNATY®)	Intramuscular injection suspension (to be diluted) Multi-dose purple cap vial (after dilution, each vial contains 6† doses of 0.3 mL) DOSE : 30mcg / 0.3mL	2 doses (8 weeks apart)* or 3+ doses (interval varies)*****	12 years of age & older at the time of vaccination
02527863	PFIZER-BIONTECH COVID-19 VACCINE	Intramuscular injection suspension	2 doses (8 weeks apart)* or	12 years of age & older at the time of vaccination

DIN or PIN	COVID-19 Vaccine Product	Dosage format	Recommended Dosing regimen**	Restrictions**
	(12+ formulation) Pfizer Canada ULC (grey cap) (also known as COMIRNATY®)	(do NOT dilute) Multi-dose grey cap vial, each vial contains 6 [†] doses of 0.3 mL DOSE : 30mcg / 0.3mL	3+ doses (interval varies)*****	
02522454	Pediatric Pfizer-BioNTech COVID-19 vaccine (orange cap) Pfizer Canada ULC (also known as COMIRNATY®)	Intramuscular injection suspension (to be diluted) Multi-dose orange cap vial (after dilution, each vial contains 10 doses of 0.2 mL) DOSE : 10 mcg / 0.2 mL	2 doses (8 weeks apart)* or 3+ doses (interval varies)*****	5 to 11 years of age at the time of vaccination
02530325	Infant Pfizer-BioNTech COVID-19 vaccine (maroon cap) Pfizer Canada ULC (also known as COMIRNATY®)	Intramuscular injection suspension (to be diluted) Multi-dose maroon cap vial (after dilution, each vial contains 10 [†] doses of 0.2 mL) DOSE : 3 mcg / 0.2 mL	3 doses (3 doses administered 8 weeks apart *****)	6 months to under 5 years of age as per product monograph
02531461	PFIZER-BIONTECH COVID-19	Intramuscular injection suspension	1 dose at least 6 months after a primary series (i.e.,	12 years of age & older at the time of vaccination

DIN or PIN	COVID-19 Vaccine Product	Dosage format	Recommended Dosing regimen**	Restrictions**
	<p>BIVALENT VACCINE</p> <p>Pfizer Canada ULC (grey cap)</p> <p>(also known as COMIRNATY®)</p>	<p>(do NOT dilute)</p> <p>Multi-dose grey cap vial, each vial contains 6[†] doses of 0.3 mL</p> <p>DOSE : 30 mcg mRNA / 0.3mL</p>	<p>2-3 doses) or after a previous booster dose</p> <p>*****</p>	
02513153	<p>Janssen COVID-19 Vaccine</p> <p>Janssen Inc.</p>	<p>Intramuscular injection solution.</p> <p>Multi-dose vial of 5 doses</p> <p>Dose: 0.5mL</p> <p>5 x 10¹⁰ VP / 0.5mL, solution, intramuscular (vial contains 5 doses of 0.5 mL)</p>	<p>1 single dose</p> <p>*****</p>	<p>18 years of age & older as per product monograph</p>
02525364	<p>Nuvaxovid™ COVID-19 Vaccine</p> <p>Novavax, Inc.</p>	<p>Suspension for intramuscular injection</p> <p>Multi-dose vial of 10 doses</p> <p>Dose: 5 mcg/ 0.5mL</p>	<p>2 doses (8 weeks apart)*</p> <p>or 3+ doses (interval varies)</p> <p>*****</p>	<p>18 years of age & older as per product monograph</p>
02521326	<p>Covifenz® COVID-19 Vaccine</p> <p>Medicago Inc.</p>	<p>As per the October 17th, 2022 update, the DIN for Covifenz® COVID-19 is no longer billable.</p>		

* Based on the [NACI statement](#), Ontario strongly recommends patients wait 8 weeks after receiving their first dose before getting a second dose. There is emerging evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness and may be

associated with a lower risk of myocarditis and/or pericarditis in adolescents and young adults. However, some eligible patient populations may receive their second dose earlier than 8 weeks if necessary, with informed consent. The appropriate minimum dose interval should be determined from the product monograph of the vaccine used for the first dose.

** Patient eligibility criteria at the pharmacy is expected to change as COVID-19 vaccine supply fluctuates and the pandemic situation evolves. NACI guidelines recommend interchangeability of vaccines (or vaccine mixing) which means a patient could receive one vaccine product for the first dose and a different vaccine product for the second dose to complete the two-dose vaccine series. For example, individuals who have received only their first dose of the COVISHIELD or AstraZeneca COVID-19 vaccine and who have not yet received a second dose should receive an mRNA (Pfizer (12+ formulation) or Moderna) vaccine for their second dose unless contraindicated. According to [NACI](#) recommendations, an mRNA vaccine is now preferred as the second dose for individuals who received a first dose of the AstraZeneca/COVISHIELD vaccine, based on emerging evidence of a potentially better immune response from this mixed vaccine schedule and to mitigate the potential risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) associated with viral vector vaccines. Please refer to the [ministry website](#) for the most recent EO Notice entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**”. Please also refer to this EO Notice for more information regarding third or booster doses with the Novavax vaccine (Nuvaxovid™) or viral vector vaccines, as well as booster (fourth or fifth) doses, repeat vaccination series for certain groups and bivalent booster doses.

*** *Footnote intentionally deleted*

**** *Footnote intentionally deleted.*

***** *Footnote intentionally deleted.*

***** For more information regarding eligibility for primary vaccine series or booster doses (including dosing intervals and half-dosing for specific age groups as well as the vaccines administered for this purpose) or the bivalent booster dose, please refer to the ministry website for the most recent EO Notice entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Eligibility”. Pharmacies should be informed and stay current with the vaccine’s official indications in accordance with Health Canada’s approved product monograph, including information regarding recommended dosing as per the product monograph. Ontario is funding third or booster doses, based on consultations with the Chief Medical Officer of Health and based on evidence and recommendations by

the [NACI](#)⁵ and the Ontario Immunization Advisory Committee (OIAC). Refer to the [ministry guidance](#) for more information.

***** Based on advice from the OIAC, and in alignment with [NACI](#), the Ministry of Health has issued a **preferential recommendation for the use of Pfizer-BioNTech COVID-19 vaccine for individuals 5-29 years of age if receiving a primary series dose, or 5-17 years of age if receiving a booster**. This recommendation stems from an observed increase in the number of reports in Ontario of myocarditis/pericarditis following vaccination with Moderna relative to Pfizer-BioNTech in children, adolescents and young adults, particularly among males. Although risk of myocarditis/pericarditis with the Moderna (50 mcg) vaccine in children 6 to 11 years of age is unknown, with a primary series in adolescents and young adults the rare risk of myocarditis/pericarditis with Moderna (100 mcg) was higher than with Pfizer-BioNTech (30 mcg). See [COVID-19 Vaccine Guidance](#) for more details.

Informed consent is required for those 6 to 29 years of age who wish to receive the Moderna vaccine, as it is whenever administering a vaccine.

***** The Janssen COVID-19 vaccine generally requires a single dose. However, individuals who received the single dose Janssen vaccine are eligible for a supplementary or booster dose and / or a bivalent booster dose in accordance with the EO Notice entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Eligibility”. For more information, please refer to the [ministry website](#) for the most recent version of that EO Notice.

***** Based on advice from the OIAC, the Ministry of Health recommends an interval between doses of 56 days (8 weeks), between dose 1 and 2 and 56 days between dose 2 and 3. However, some eligible individuals may receive their second dose earlier than 56 days (8 weeks) if necessary, with informed consent. The appropriate minimum dose interval should be determined from the product monograph. The 56-day (8-week) interval between dose 2 and 3 cannot be reduced. For more information, please refer to the [ministry website](#) for the most recent version of the EO Notice entitled “Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Eligibility”.

†Low dead-volume syringes and/or needles can be used to extract extra doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract an extra dose from a single vial. Vial labels and cartons may state that after dilution, a vial contains 5 or 10 doses. The information in the Product Monograph regarding the number of doses per vial after dilution supersedes the number of doses stated on the vial labels and cartons.

⁵ Nuvaxovid™ COVID-19 vaccine is currently not authorized by Health Canada for use as a booster dose in Canada. However, a booster is recommended as per [NACI](#) for individuals without contraindications to Nuvaxovid who are not able or willing to receive an mRNA vaccine.

Billing Procedures – Summary

- Claims for administering the publicly funded COVID-19 vaccine can only be submitted electronically using the HNS (see “Billing Procedures - Detailed” below). No manual paper claims will be accepted unless 3 intervention codes are required in order to process the claim.
- The Part A pharmacist who administers the vaccine or who is overseeing other pharmacy staff administering the vaccine must be identified in the prescriber field on the claim. Each claim must include the Drug Identification Number (DIN) corresponding to the publicly funded COVID-19 vaccine that was administered to the patient (see Table 1 above).
- The person submitting the claim must ensure that the patient’s date of birth, Ontario health number and name (as it appears on the health card / document) are included in the claim. Failure to do so – especially for non-Ontario Drug Benefit (ODB) Program recipients – may impact the ability to submit future claims for these patients.
 - **For patients without an Ontario health card number, pharmacies must use the proxy patient ID: 79999 999 93 (see below for further details).**

Pharmacy Documentation Requirements

Pharmacies must keep a record of every dose of publicly funded COVID-19 vaccine administered.

Pharmacists shall keep records consistent with their obligations under the *Pharmacy Act, 1991*, the *Drug and Pharmacies Regulation Act*, the COVID-19 Vaccine Agreement, and any instructions or guidelines provided by the OCP or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for administering a publicly funded COVID-19 vaccine must be maintained in a readily available format for the purpose of ministry inspection for a minimum of 10 years from the last recorded pharmacy service provided to the patient, or until 10 years after the day on which the patient reached or would have reached the age of 18 years, whichever is longer.

Overpayments due to inappropriate claim submissions are subject to recovery.

Pharmacy documentation must be maintained in a readily retrievable format and record requirements are:

- Record of name and address of patient.
- Record of patient's health number or alternate ID with contact information if applicable.
- In the case of patients who receive the Nuvaxovid™ or a viral vector (Janssen) vaccine due to an allergy to an mRNA vaccine, the COVID-19 Vaccination: Allergy Form.⁶
- In the case of immunocompromised individuals eligible to receive booster dose(s) after a 3-dose primary series, as applicable,⁷ a copy of the referral letter from their health care provider OR pharmacist documentation that the patient is taking an immunosuppressive medication listed [here](#), based on the pharmacist's examination of the patient's recent prescription label or prescription receipt or their medication profile.
- Record of name of vaccine administered, dose (including half-dosing if applicable), lot number, expiry date, time, date, route and site of administration.
- Record of pharmacy name, pharmacy address and name and signature of individual who administered the vaccine.
- Record of location of administration (inside pharmacy, pharmacy parking lot or within the retirement home, elderly congregate setting, long-term care home or location of a mobile clinic if applicable)
- Evidence of the provision of a written and electronic (if applicable) record of the COVID-19 immunization record to the patient, which includes the pharmacy's contact information and date and time for the second scheduled dose at the same pharmacy location. Note: date and time of the second dose may be hand-written on the written record provided to the patient.
- Record of any serious adverse events following immunization that result in the administration of epinephrine, and the circumstances relating to the administration of the substance.
- Records documenting compliance with any requirements to access and use the Provincial COVID-19 Vaccine Solution-COVAX_{ON} under the COVID-19 Vaccine Agreement. Note: All respective health care providers whether pharmacist, intern, registered pharmacy student, pharmacy technician or other health care provider must identify themselves as the vaccinator in the COVAX_{ON} system and on the vaccine receipt provided to the patient.

⁶ For more information on when this documentation is required, see the most recent [EO Notice](#) entitled "Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Eligibility".

⁷ For more information on when this documentation is required, see the most recent [EO Notice](#) entitled "Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Eligibility".

Billing Procedures – Detailed

Claims submission requirements for administering publicly funded COVID-19 vaccines are as follows:

For ODB-eligible recipients

The claim submission follows the usual process (See [Section 5](#) of the Ontario Drug Program Reference Manual) for submitting claims on the HNS with the following additional information:

- Intervention code 'PS': (Professional Care Services)
- Drug Identification Number (DIN): as per the publicly funded COVID-19 vaccine administered (see Table 1 above)
- Valid Pharmacist ID

For Non-ODB recipients

When submitting a claim for a person who does not have ODB coverage, pharmacists must submit the following information:

- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Patient's Ontario Health Card number*
- Intervention codes:
 - PS: Professional Care Services
 - ML: Established eligibility coverage (i.e., 1 day of the Plan 'S' coverage)
- Carrier ID: 'S'
- Drug Identification Number (DIN): as per the publicly funded COVID-19 vaccine administered
- Valid Pharmacist ID

For patients without an Ontario health number

When submitting a claim for any eligible person who does not have an Ontario health number, pharmacists must submit the following information:

- First Name: Patient's first name
- Last Name: Patient's last name
- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Proxy patient ID: 79999 999 93
- Intervention codes:
 - PS: Professional Care Services
 - PB: Name entered is consistent with card
- Valid Pharmacist ID

Exclusions and Restrictions

- If a patient does not have a valid Ontario health card number, pharmacy staff can still administer the publicly funded COVID-19 vaccine, provided that the patient provides an alternate identification confirming their name and date of birth. In such cases, pharmacies must use the proxy patient ID: 79999 999 93.
- Administration of non-publicly funded COVID-19 vaccines that are privately purchased by the pharmacy does not qualify for payment.
- Pharmacies may not transfer publicly funded COVID-19 vaccine inventory to another pharmacy unless specifically approved by the ministry. See the most recent version of the accompanying Questions & Answers for Pharmacies for more information.
- Vaccine administration must occur at the location of the participating pharmacy premises, unless otherwise indicated. The pharmacy is permitted to administer publicly funded vaccines supplied by their distributor in a nearby location (e.g., an adjacent pharmacy parking lot) and retirement homes, elderly congregate settings, long-term care homes, or mobile clinic locations as long as they are able to ensure adherence to public safety and relevant Ministry policy / direction (including infection prevention and control measures), the COVID-19 Vaccine Agreement, and any Ontario College of Pharmacist (OCP) standards, policies or guidelines. See the most recent version of the accompanying Questions & Answers for Pharmacies for more information.
- The role of pharmacists, pharmacy students, interns or pharmacy technicians administering the COVID-19 vaccine in initiatives led by other authorized

organizations that have entered into COVID-19 Vaccine Agreements with the Ministry (e.g., public health units or hospitals that organize mass immunization clinics) that are not billed through the HNS is excluded from this notice.

- A pharmacist’s recommendation to a prescriber that a patient should receive a COVID-19 vaccine is not a billable service under the Pharmaceutical Opinion Program.

Payment for epinephrine auto-injector for emergency treatment after administration of the COVID-19 vaccine

In the event of an adverse event resulting immediately after pharmacy staff administers a publicly funded COVID-19 vaccine, the ministry will reimburse pharmacies for the acquisition cost of the epinephrine auto-injector up to the total amount reimbursed (see Table 2). Emergency treatment must take place in the pharmacy or where the vaccine was administered, for example an adjacent pharmacy parking lot, retirement home, long-term care home, other congregate setting, or mobile clinic location, if applicable.

Table 2: Epinephrine products and reimbursement if required post COVID-19 vaccine administration

PIN	Epinephrine Product	Total Amount Reimbursed
09857423	Epipen 1/1000 (1mg/1mL) DIN 00509558	\$94.44
09857424	Epipen Jr. 0.5mg/mL DIN 00578657	\$94.44
09857439	Allerject 0.15mg/0.15mL DIN 02382059	\$94.44
09857440	Allerject 0.3mg/0.3mL DIN 02382067	\$94.44
09858129	Emerade 0.3mg/0.3mL Inj DIN 02458446	\$85.54
09858130	Emerade 0.5mg/0.5mL Inj DIN 02458454	\$85.54

Billing Procedures – Epinephrine Auto-Injector for Emergency

The value indicated in the 'Total Amount Reimbursed' column (Table 2) will be paid by the ministry for each valid claim for administering epinephrine auto-injector.

Pharmacy staff must use the product identification number (PIN) of the epinephrine product and bill as a second claim following the COVID-19 vaccine administration claim on the same day of service. Pharmacies cannot enter the DIN, a mark-up or a dispensing fee in the claim.

The ministry does not accept paper claims for the administration of epinephrine auto-injector unless 3 intervention codes are required in order to process the claim.

For ODB-eligible recipients

The claim submission follows the usual process (See [Section 5](#) of the Ontario Drug Program Reference Manual) for submitting claims on the HNS with the following additional information:

- Intervention code 'PS': Professional Care Services
- Product Identification Number (PIN): as per the epinephrine auto-injection administered (see above)
- Valid Pharmacist ID

For Non-ODB recipients

When submitting a claim for a person who does not have ODB coverage, pharmacists must submit the following information:

- Patient's Ontario health card number*
- Intervention codes PS: Professional Care Services
- Product Identification Number (PIN): as per the epinephrine auto-injection administered (see Table 2 above)
- Valid Pharmacist ID code must be included with the claim

***For patients without an Ontario health number**

When submitting a claim** for any eligible person who does not have an Ontario health number, pharmacists must submit the following information:

- First Name: Patient's first name
- Last Name: Patient's last name
- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Proxy patient ID: 79999 999 93
- Intervention codes:
 - PS: Professional Care Services
 - PB: Name entered is consistent with card
- Valid Pharmacist ID

Restrictions on Epinephrine Auto-Injection

Epinephrine auto-injection will not be reimbursed in the following situations:

- Providing the epinephrine auto-injection to the patient to self-administer or take home (for example: in the event the patient may experience an adverse event after leaving the pharmacy).
- Pharmacist emergency injection of epinephrine auto-injection not due to an adverse drug reaction resulting from the administration of the publicly funded COVID-19 vaccine.

Prior EO Notices

- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies, (Effective Date March 10, 2021).
- Executive Officer Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing, (Effective Date March 22, 2021).
- Executive Officer Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing, (Effective Date April 1, 2021).
- Executive Officer Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing, (Effective Date April 19, 2021).
- Executive Officer Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing, (Effective Date April 30, 2021).
- Executive Officer Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing, (Effective Date May 6, 2021).

- Executive Officer Notice: Pause of the Administration of First Doses of Publicly Funded AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies (May 11, 2021)
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective May 13, 2021).
- Executive Officer Notice: Administration of Second Doses for Individuals who received First Dose of AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies (May 21, 2021)
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective May 31, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective June 4, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective June 14, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective June 17, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective June 25, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective July 5, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective August 18, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective September 1, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective September 8, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective October 1, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective October 8, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective November 3, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective November 25, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective December 2, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective December 17, 2021).

- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective December 20, 2021).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective January 13, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective February 18, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective March 25, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective April 7, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective May 2, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective July 14, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective July 28, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective August 8^t, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective September 1, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective September 12, 2022).
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Billing, (Effective September 26, 2022).

Additional Information:**For pharmacy billing:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For Support for Provincial COVID-19 Vaccine Solution-COVAX_{ON}:

Please contact your pharmacy head office or the [Ontario Pharmacists Association](#) or the [Neighbourhood Pharmacy Association of Canada](#)

For COVID-19 vaccine rollout in pharmacy:

Please email the ministry at: OPDPInfoBox@ontario.ca

For Ministry COVID-19 Vaccine-Relevant Information and Planning Resources

Please access this [website](#)

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.